A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide

Highlights • Immunotherapy represents an emerging and promising therapeutic approach in NSCLC. • hTERT plays a critical role in tumor cell growth and survival. • Vx-001 has been shown able to mount specific and durable immune responses. • Immune response seems to be correlated with improvement of th...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2014-10, Vol.86 (1), p.59-66
Main Authors: Kotsakis, Athanasios, Papadimitraki, Elisavet, Vetsika, Eleni Kyriaki, Aggouraki, Despoina, Dermitzaki, Eleftheria Kleio, Hatzidaki, Dora, Kentepozidis, Nikolaos, Mavroudis, Dimitris, Georgoulias, Vassilis
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Cancer Vaccines - administration & dosage
Cancer Vaccines - adverse effects
Cancer Vaccines - immunology
Carcinoma, Non-Small-Cell Lung - immunology
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Chemotherapy, Adjuvant
Clinical efficacy
Disease Progression
Female
h-TERT
Hematology, Oncology and Palliative Medicine
HLA-A2
HLA-A2 Antigen - immunology
Humans
Immunologic response
Immunotherapy
Lung Neoplasms - immunology
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
NSCLC
Peptide Fragments - immunology
Phase II
Pneumology
Pulmonary/Respiratory
Radiotherapy, Adjuvant
Telomerase - chemistry
Telomerase - immunology
Treatment Outcome
Tumors
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Immunotherapy represents an emerging and promising therapeutic approach in NSCLC. • hTERT plays a critical role in tumor cell growth and survival. • Vx-001 has been shown able to mount specific and durable immune responses. • Immune response seems to be correlated with improvement of the clinical outcome.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2014.07.018